Latest News
& Press Releases

Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.

Jeanne Marrazzo, former director of the National Institutes of Allergy and Infectious Disease, was formally terminated Thursday after months on administrative leave, after filing a whistleblower report.

Expanded exemptions for orphan drugs could mean prolonged protections for top-selling drugs like Merck’s Keytruda, which was initially approved under this designation in 2014.

Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients without prior cardiovascular disease, for which the drug was approved in August 2024.

Following up on previous, dimly received issuances, a new set of ideas published by the FDA to streamline regulatory pathways for cell and gene therapies ‘for small populations’ is receiving a warmer welcome—but experts warn it will take more to turn the tide for the fraught therapeutic space.

Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.

Looking for a biopharma job in Boston? Check out the BioSpace list of six companies hiring life sciences professionals like you.

In this episode presented by PII, BioSpace’s head of insights discusses with guests Oliver Eden and Travis Webb how autoinjectors offer opportunities to improve delivery systems, patient compliance and clinical trial processes.

Both Halozyme and Elektrofi have partnered with several Big Pharma companies to provide drug delivery technologies.

President Donald Trump last week announced that 100% pharma tariffs would come Oct. 1, but a White House official has clarified that that’s when the government will “begin preparing” the levies.

Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move.

With layoffs happening at biopharma companies of all sizes, some may wonder which jobs are safest. Talent acquisition experts spoke to BioSpace about the areas and roles they recommend to biotech and pharma professionals hoping to avoid staff cuts.

The company highlights the critical role of unified digital platforms in ensuring compliance, sponsor trust, and clinical readiness.

Highlights ● Insilico published a new study unveiling Target Identification Pro (TargetPro), a superior disease-specific model, and TargetBench 1.0, the first standardized benchmarking framework for target discovery. ● TargetPro achieved 71.6% retrieval of known clinical targets, a 2–3x improvement over large language models (LLMs) such as GPT-4o, Grok3, DeepSeek-R1, Claude-Opus-4, BioGPT, and public platforms like Open Targets. ● TargetPro’s predicted novel targets demonstrated 95.7% structure availability, 86.5% druggability, and 46% repurposing potential, outperforming competing systems on all measures. ● TargetBench’s explainable AI models revealed disease-specific feature importance patterns, emphasizing the value of disease-specific target identification models. ● New gold standard approaches improve accuracy, reliability, and transparency in AI-driven drug discovery.